AnaptysBio Company Insiders
| ANAB Stock | USD 46.21 0.53 1.16% |
About 66 percent of all AnaptysBio's insiders are acquiring. The analysis of the overall insider sentiment regarding AnaptysBio suggests that quite a large number of insiders are confidant. AnaptysBio employs about 136 people. The company is managed by 15 executives with a total tenure of roughly 8 years, averaging almost 0.0 years of service per executive, having 9.07 employees per reported executive.
| Eric Loumeau Executive General Counsel |
Insider Sentiment 66
Mostly Buying
Selling | Buying |
Latest Trades
| 2025-07-02 | Hollings Renton | Disposed 20925 @ 23.57 | View | ||
| 2025-01-02 | Ecor1 Capital, Llc | Acquired 6646 @ 12.95 | View | ||
| 2024-12-30 | Ecor1 Capital, Llc | Acquired 65184 @ 12.92 | View |
Monitoring AnaptysBio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
AnaptysBio | Build AI portfolio with AnaptysBio Stock |
AnaptysBio's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with AnaptysBio's future performance. Based on our forecasts, it is anticipated that AnaptysBio will maintain a workforce of about 140 employees by February 2026.AnaptysBio Management Team Effectiveness
The company has return on total asset (ROA) of (0.0423) % which means that it has lost $0.0423 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.0802) %, meaning that it created substantial loss on money invested by shareholders. AnaptysBio's management efficiency ratios could be used to measure how well AnaptysBio manages its routine affairs as well as how well it operates its assets and liabilities. As of January 21, 2026, Return On Tangible Assets is expected to decline to -0.28. In addition to that, Return On Capital Employed is expected to decline to -0.25. At present, AnaptysBio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.72, whereas Total Assets are forecasted to decline to about 369.2 M.As of January 21, 2026, Common Stock Shares Outstanding is expected to decline to about 20 M. The current year's Net Loss is expected to grow to about (110.1 M)The majority of AnaptysBio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AnaptysBio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AnaptysBio. Please pay attention to any change in the institutional holdings of AnaptysBio as this could imply that something significant has changed or is about to change at the company.
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 28.8 M | Current Value 29 M | Avarage Shares Outstanding 20.4 M | Quarterly Volatility 10.8 M |
AnaptysBio Workforce Comparison
AnaptysBio is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,864. AnaptysBio holds roughly 136 in number of employees claiming about 7% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.5) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.45 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.45. AnaptysBio Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AnaptysBio insiders, such as employees or executives, is commonly permitted as long as it does not rely on AnaptysBio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AnaptysBio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2026-03-01 | 1.1667 | 35 | 30 | 598,897 | 237,061 |
| 2025-12-01 | 0.3889 | 7 | 18 | 54,000 | 128,834 |
| 2025-09-01 | 0.4444 | 4 | 9 | 37,456 | 76,852 |
| 2025-06-01 | 0.7 | 7 | 10 | 43,510 | 49,540 |
| 2025-03-01 | 1.8889 | 34 | 18 | 1,051,330 | 174,625 |
| 2024-12-01 | 1.5 | 3 | 2 | 88,452 | 20,000 |
| 2024-09-01 | 0.7143 | 15 | 21 | 573,272 | 91,240 |
| 2024-06-01 | 0.7 | 7 | 10 | 26,069 | 28,235 |
| 2024-03-01 | 1.9286 | 27 | 14 | 1,106,535 | 558,136 |
| 2023-09-01 | 0.875 | 7 | 8 | 37,846 | 32,105 |
| 2022-09-01 | 3.0 | 3 | 1 | 36,000 | 523.00 |
| 2022-06-01 | 2.0 | 8 | 4 | 1,388,974 | 1,340,120 |
| 2021-12-01 | 0.8667 | 13 | 15 | 131,381 | 223,231 |
| 2021-09-01 | 1.0 | 1 | 1 | 10,000 | 10,000 |
| 2021-06-01 | 7.0 | 7 | 1 | 378,800 | 10,000 |
| 2021-03-01 | 8.5 | 17 | 2 | 3,691,784 | 20,000 |
| 2020-12-01 | 0.6667 | 2 | 3 | 48,958 | 1,416,747 |
| 2020-03-01 | 4.0 | 8 | 2 | 86,000 | 20,000 |
| 2019-12-01 | 3.0 | 6 | 2 | 535,802 | 56,202 |
| 2019-09-01 | 3.0 | 3 | 1 | 25,768 | 0.00 |
| 2019-06-01 | 0.2 | 2 | 10 | 20,060 | 52,548 |
| 2019-03-01 | 1.5714 | 11 | 7 | 200,075 | 212,150 |
| 2018-12-01 | 0.2222 | 6 | 27 | 169,363 | 466,224 |
| 2018-09-01 | 1.0 | 4 | 4 | 190,493 | 150,493 |
| 2018-06-01 | 0.25 | 3 | 12 | 355,306 | 4,472,452 |
| 2018-03-01 | 13.0 | 13 | 1 | 183,990 | 16,483 |
| 2017-09-01 | 0.2727 | 3 | 11 | 76,305 | 1,533,927 |
| 2017-03-01 | 0.6087 | 42 | 69 | 14,848,215 | 18,629,677 |
AnaptysBio Notable Stakeholders
An AnaptysBio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AnaptysBio often face trade-offs trying to please all of them. AnaptysBio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AnaptysBio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Martin Dahl | Senior Research | Profile | |
| Monique Silva | Senior Affairs | Profile | |
| James MD | Advisor | Profile | |
| David McKeon | Senior Controller | Profile | |
| Beth Mueller | Senior Resources | Profile | |
| Priya Raina | Senior Operations | Profile | |
| FAAD MBA | Chief Officer | Profile | |
| Daniel Faga | Interim Director | Profile | |
| MSc MBA | Advisory | Profile | |
| Dennis Mulroy | Chief Officer | Profile | |
| Douglas MBA | Senior CMC | Profile | |
| Eric Loumeau | General Counsel | Profile | |
| Benjamin Stone | Chief Officer | Profile | |
| MSc MD | Senior Development | Profile | |
| MD FACR | Senior Medicine | Profile |
About AnaptysBio Management Performance
The success or failure of an entity such as AnaptysBio often depends on how effective the management is. AnaptysBio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AnaptysBio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AnaptysBio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | (1.84) | (1.94) |
Please note, the presentation of AnaptysBio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AnaptysBio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AnaptysBio's management manipulating its earnings.
AnaptysBio Workforce Analysis
Traditionally, organizations such as AnaptysBio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AnaptysBio within its industry.AnaptysBio Manpower Efficiency
Return on AnaptysBio Manpower
| Revenue Per Employee | 671.2K | |
| Revenue Per Executive | 6.1M | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 9.7M | |
| Working Capital Per Employee | 2.8M | |
| Working Capital Per Executive | 25.8M |
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities |